A detailed history of Tfc Financial Management transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Tfc Financial Management holds 758 shares of CRSP stock, worth $36,293. This represents 0.01% of its overall portfolio holdings.

Number of Shares
758
Previous 700 8.29%
Holding current value
$36,293
Previous $37,000 5.41%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$44.62 - $62.75 $2,587 - $3,639
58 Added 8.29%
758 $35,000
Q4 2023

Jan 25, 2024

BUY
$38.62 - $72.18 $26,261 - $49,082
680 Added 3400.0%
700 $43,000
Q1 2022

May 04, 2022

SELL
$53.19 - $79.24 $14,308 - $21,315
-269 Reduced 93.08%
20 $1,000
Q4 2020

Feb 10, 2021

BUY
$79.67 - $173.23 $1,593 - $3,464
20 Added 7.43%
289 $44,000
Q3 2020

Nov 12, 2020

BUY
$78.5 - $100.64 $21,116 - $27,072
269 New
269 $22,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.74B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Tfc Financial Management Portfolio

Follow Tfc Financial Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tfc Financial Management, based on Form 13F filings with the SEC.

News

Stay updated on Tfc Financial Management with notifications on news.